Droz Jean-Pierre, Aapro Matti, Balducci Lodovico
Department of Medical Oncology, Claude Bernard Lyon 1 University, Centre Léon Bérard, Lyon, France.
Crit Rev Oncol Hematol. 2008 Oct;68 Suppl 1:S1-8. doi: 10.1016/j.critrevonc.2008.07.005. Epub 2008 Aug 26.
Prostate, breast, colorectal, and lung cancer have a high prevalence in the senior adult population. Traditionally, senior adult patients have been viewed as too frail to cope with chemotherapy; however, some patients can benefit from such treatment. This review emphasizes the heterogeneity of the senior adult population and the need to make treatment decisions on a case-by-case basis. Suitability for chemotherapy should be determined by assessment of functional status, performance status, life expectancy, and existing comorbidities. These factors can be evaluated by means of a comprehensive geriatric assessment, aiding treatment decisions. To ensure the safe administration of chemotherapy to elderly patients, awareness of the physiological changes associated with aging and when to make dose adjustments is required. With the global demographic shift towards a more elderly population and continuing advances in cancer treatment, it is imperative that chronologic age alone does not prevent senior adult patients from receiving chemotherapy and care in line with best practice.
前列腺癌、乳腺癌、结直肠癌和肺癌在老年人群中具有较高的发病率。传统上，老年患者被认为过于虚弱而无法耐受化疗；然而，一些患者可以从这种治疗中获益。本综述强调了老年人群的异质性以及根据具体情况做出治疗决策的必要性。化疗的适用性应通过评估功能状态、体能状态、预期寿命和现有合并症来确定。这些因素可通过全面的老年评估进行评估，以辅助治疗决策。为确保老年患者安全进行化疗，需要了解与衰老相关的生理变化以及何时进行剂量调整。随着全球人口结构向老龄化转变以及癌症治疗的不断进步，仅按年龄不应妨碍老年患者接受符合最佳实践的化疗和护理。
